A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand® Automated Process, and Injected in Patients With an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% After PTCA and Stent(s) Implantation Versus Standard of Care.

Trial Profile

A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand® Automated Process, and Injected in Patients With an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% After PTCA and Stent(s) Implantation Versus Standard of Care.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Endothelial stem cell therapy (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions
  • Acronyms EXCELLENT
  • Sponsors CellProthera
  • Most Recent Events

    • 12 Nov 2017 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
    • 12 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
    • 12 May 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top